Department of Respiratory Medicine, the Second Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510120, China.
J Thorac Dis. 2012 Jun 1;4(3):310-5. doi: 10.3978/j.issn.2072-1439.2012.01.09.
Chronic obstructive pulmonary disease (COPD) and chronic heart failure (CHF) frequently coexist in clinical practice as they share the same risk factors. The manifestations of COPD and CHF are similar. Exertional dyspnoea, easy fatigability and reduced exercise tolerance are common to COPD and CHF and required careful interpretation. Pulmonary function tests, plasma natriuretic peptides, echocardiography and cardiovascular magnetic resonance imaging should be carried out to acquire the objective evidence of pulmonary and cardiac function when necessary. Robust studies indicate that patients with COPD tolerate the cardioselective β-blockers well, so it should not be denied to CHF patients with concomitant COPD. Low-dose initiation and gradual uptitration of cardioselective β-blockers is currently recommended. However, β(2)-agonists should be used with cautions in COPD patients with CHF, especially in acute exacerbations. Statins, angiotensin-converting enzyme inhibitors, and angiotensin-receptor blockers may reduce the morbidity and mortality of the patients with COPD.
慢性阻塞性肺疾病(COPD)和慢性心力衰竭(CHF)在临床实践中经常同时存在,因为它们有共同的危险因素。COPD 和 CHF 的临床表现相似。劳力性呼吸困难、易疲劳和运动耐量降低是 COPD 和 CHF 的共同表现,需要仔细解释。当需要获取肺和心脏功能的客观证据时,应进行肺功能检查、血浆利钠肽、超声心动图和心血管磁共振成像。有力的研究表明,COPD 患者能很好地耐受心脏选择性β受体阻滞剂,因此不应拒绝同时患有 COPD 的 CHF 患者使用。目前建议低剂量起始并逐渐增量给予心脏选择性β受体阻滞剂。然而,在伴有 CHF 的 COPD 患者中应谨慎使用β(2)-激动剂,特别是在急性加重期。他汀类药物、血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂可能降低 COPD 患者的发病率和死亡率。